Welcome to our dedicated page for Legend Biotech news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech stock.
Legend Biotech Corporation (NASDAQ: LEGN) generates frequent news as a global cell therapy company focused on CAR‑T treatments for cancer. News coverage for Legend Biotech often centers on CARVYKTI® (ciltacabtagene autoleucel; cilta‑cel), its BCMA‑targeted CAR‑T cell therapy for relapsed or refractory multiple myeloma, as well as updates on its broader pipeline of cell therapy programs.
Investors and observers following LEGN news can expect regular announcements on clinical data from the CARTITUDE program in multiple myeloma, including long‑term progression‑free survival results and analyses of earlier‑line use. Company press releases also highlight presentations at major medical meetings such as the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA), where Legend Biotech shares outcomes from CARVYKTI and investigational candidates like LUCAR‑G39D, LB2102, and LB1908.
Legend Biotech’s news flow includes regulatory milestones, such as FDA and European Commission label updates for CARVYKTI to incorporate overall survival data and new safety information. The company also reports on manufacturing and infrastructure developments, including expansion of its Raritan, New Jersey cell therapy facility and commercial production in Ghent, Belgium, which are intended to support growing global demand.
Quarterly earnings releases and related Form 6‑K filings provide financial updates on collaboration revenue from CARVYKTI, license revenue from agreements with partners, operating expenses, cash and time deposits, and progress toward profitability. Corporate news items may also cover executive appointments, participation in investor conferences, and strategic priorities outlined at healthcare investment events.
For users tracking LEGN, this news page offers a centralized view of Legend Biotech’s clinical, regulatory, manufacturing, and financial announcements, helping contextualize the company’s evolution in the cell therapy and oncology landscape.
Legend Biotech (NASDAQ: LEGN), a global leader in cell therapy, has announced it will host an investor conference call on Tuesday, March 11, 2025, at 8:00 am ET to review its fourth quarter and full year 2024 financial results.
During the webcast and conference call, senior leadership will provide an overview of Legend Biotech's quarterly and fiscal year performance. Investors and interested parties can join the live audio webcast via a provided weblink.
A replay of the webcast and the earnings news release will be made available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approximately two hours after the call concludes.
Legend Biotech (NASDAQ: LEGN), a global cell therapy leader, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Ying Huang, Ph.D., will deliver company updates at the event in San Francisco on January 14, 2025, at 3:45 p.m. PT. The presentation will be accessible via live audio webcast through Legend's Investor Relations website section, with a replay available approximately 48 hours after the event.
Legend Biotech (NASDAQ: LEGN) announced new results from the Phase 3 CARTITUDE-4 study showing CARVYKTI® achieved significantly higher minimal residual disease (MRD) negativity rates compared to standard therapies in multiple myeloma patients. 89% of evaluable patients achieved MRD negativity with CARVYKTI® after three-year follow-up, versus 38% for standard therapies.
The study evaluated 208 adults receiving CARVYKTI® versus 211 receiving standard therapies. 69% of MRD-evaluable patients achieved negativity by day 56, and sustained MRD-negative ≥CR of at least 12 months was achieved in 52% versus 10% in the standard care arm. CARVYKTI® is now commercially available in five countries and has been used by over 4,500 patients.
Legend Biotech (LEGN) reported Q3 2024 results with CARVYKTI® net trade sales of $286 million, showing 87.6% year-over-year and 53.2% quarter-over-quarter growth. The company initiated commercial production at its new Obelisc facility in Belgium and received multiple regulatory approvals, including China's NMPA approval for fourth-line plus multiple myeloma treatment. Financial highlights include collaboration revenue of $142.8 million, license revenue of $17.1 million, and a net loss of $125.3 million. With $1.2 billion in cash and equivalents, Legend expects financial runway into 2026, anticipating operating profit achievement.
Legend Biotech (NASDAQ: LEGN) has announced an upcoming investor event during the 66th ASH Annual Meeting in San Diego. The live webcast is scheduled for December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET). CEO Ying Huang and CMO Mythili Koneru will host expert clinicians to discuss updates from the CARTITUDE development program. Investors can access the webcast through a provided weblink or the company's website under Events and Presentation section.
Legend Biotech will present new minimal residual disease (MRD) negativity data from the Phase 3 CARTITUDE-4 trial at the 66th ASH Annual Meeting. The study evaluated CARVYKTI versus standard of care in lenalidomide-refractory multiple myeloma patients who received 1-3 prior therapies. The data shows significantly increased and sustained MRD negativity rates, supporting CARVYKTI as a transformative treatment option. CARVYKTI, the first BCMA-targeted CAR-T cell therapy approved for multiple myeloma after one prior line of therapy, is now available in five countries and has treated over 4,000 patients.
Legend Biotech (NASDAQ: LEGN) has appointed Alan Bash as President of CARVYKTI® in a newly created position. Bash will manage CARVYKTI's continued growth and oversee commercial, technical operations, and quality functions. The appointment follows CARVYKTI's recent FDA and European Commission approvals for label expansion. Bash brings extensive experience as former CEO of ZielBio and Checkmate Pharmaceuticals, plus a 23-year career at Bristol Myers Squibb where he led the U.S. launch of Opdivo® and expansion of other cancer treatments. CARVYKTI is currently the fastest launched CAR-T product on the market.
Legend Biotech (NASDAQ: LEGN) has announced it will host an investor conference call on Tuesday, November 12, 2024, at 8:00 am ET to discuss third-quarter 2024 financial results. Senior leadership will present the company's quarterly performance during the call. Investors can access the live audio webcast through a provided weblink, with a replay and earnings release available on the company's Investor Relations website approximately two hours after the call.
Legend Biotech (NASDAQ: LEGN) has announced plans to establish a new 31,000 square-foot state-of-the-art research and development facility in Philadelphia, Pennsylvania. This expansion aims to enhance Legend's cell therapy portfolio and expand its R&D capabilities as a global cell therapy leader. The facility, located at 2300 Market Street, is expected to be completed in the third quarter of 2025 and will eventually house 55 full-time employees.
This new site adds to Legend's existing global R&D organization, which includes over 350 employees worldwide. The company, with over 1,200 employees in the United States, views this expansion as an opportunity to join Philadelphia's growing biotech community, attract top talent, and strengthen partnerships with local research institutions.
Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN). The partnership aims to apply advanced robotic technology to cell therapy manufacturing.
Multiply Labs' approach involves robotic systems that can operate various instruments already used in the cell and gene therapy industry, potentially enabling faster adoption of robotic technology. Legend Biotech will evaluate Multiply Labs' robotic technologies and secure priority access to these automated systems.
The collaboration's template is based on a peer-reviewed study published in Cytotherapy, which demonstrated statistical equivalence between manual and automated cell expansion processes. This initiative could lead to reduced labor costs and increased manufacturing throughput in the future.